Patent SG-11201407793T-A (SG)
Title: Compounds and compositions for modulating egfr activity
Inventor: LELAIS GERALD
IPC: C07D513/04
Filed: 2013-06-05
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 December 2013 (12.12.2013) WIPOIPCT (10) International Publication Number WO 2013/184757 A1 (51) International Patent Classification: C07D 401/14 (2006.01) C07D 413/04 (2006.01) C07D 413/14 (2006.01) C07D 471/04 (2006.01) C07D 403/04 (2006.01) C07D 513/04 (2006.01) C07D 403/14 (2006.01) A61K31/4439 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/044247 5 June 2013 (05.06.2013) English English (30) Priority Data: 1741/DEL/2012 6 June 2012 (06.06.2012) IN 61/770,752 28 February 2013 (28.02.2013) US (71) Applicant (for all designated States except US): IRM LLC [US/US]; 131 Front Street, P.O. Box HM 2899, Hamilton, HM LX (BM). (72) Inventors; and (71) Applicants (for US only)-. LELAIS, Gerald [CH/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). EPPLE, Robert [AT/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hop­ kins Drive, San Diego, California 92121 (US). MARSILJE, III, Thomas H. [US/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hop­ kins Drive, San Diego, California 92121 (US). MICHELLYS, Pierre-Yves [US/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hop­ kins Drive, San Diego, California 92121 (US). MCNEILL, Matthew H. [US/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hop­ kins Drive, San Diego, California 92121 (US). LONG, Yun [US/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). LU, Wenshuo [CA/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). CHEN, Bei [US/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). BURSULAYA, Badry [US/US]; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). JIANG, Songchun [US/US]; Gen­ omics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121 (US). (74) Agents: TONGCO WU, Emily et al.; Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hop­ kins Drive, San Diego, California 92121 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) Published: — with international search report (Art. 21(3)) l> i> oo i-H o CJ (54) Title: COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY (57) Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or dereg - ulated EGFR activity.